ROI-21-0520 Honeywell International Inc.: Microarray Portfolio - 30 assets

11 US issued patents and 19 international counterparts (CN, JP, EP, IN) across 12 families related to microarray technology, including patents related to Polymerase Chain Reaction (PCR) or real-time PCR, one of the diagnostic procedures for identifying pathogens, as well as to test kits (e.g., microarray readers) used to detect large amounts of biological material. 

Broker listed companies and products of potential interest: Accelerate Diagnostics, BioFire, Biogenex, CapitalBio, Charles River Laboratories, Eurofins Scientific, Evonetix, Exagen, Friz Biochem, GenMark Diagnostics, HTG Molecular Diagnostics, Illumina, Jiangsu Hechuang Biotechnology, Lucira Health, Microbio, Molecular Devices, Myriad Genetics, Nanosphere Health, NEXTGENPCR, Occam Biolabs, Perkin Elmer, QIAGEN, Roche Diagnostics, T2 Biosystems, and Thermo Fisher Scientific, among many others.

More information available upon request and under NDA. 

 

Package data provided by Richardson Oliver Insights. 

Contact info: Gustavo Aray at gustavo@rzv-ip.com, or use the IAM Market message form to get in touch.

Transactions: 

Company details

Send message

Please register to send messages.